Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Inclusion Criteria:

- Subjects who have participated in a randomized "qualifying" study of CP-690,550 for
the treatment of rheumatoid arthritis

Vaccine sub-study visit

- Subjects actively participating in Study A3921024 must have completed at least 3
months of continuous 10 mg BID CP-690,550 treatment in A3921024 as defined by >80%
compliance with prescribed dose consumption of CP-690,550 over the previous 3 months.

Exclusion Criteria:

- Serious medical conditions that would make treatment with CP-690,550 potentially
unsafe

Vaccine sub-study visit

1. Any documented influenza or pneumococcal infection within the last 3 months prior to
randomization in this study

2. Received any vaccine within 1 month prior to randomization in this study

3. Received an influenza vaccine within 6 months or a pneumococcal vaccine within 5 years
of randomization in this study.